Sonesitatug Vedotin

DRUG3 trials

Sponsors

Jeeyun Lee, AstraZeneca

Conditions

Esophageal CancerGastric CancerGastroesophageal AdenocarcinomaGastroesophageal Junction AdenocarcinomaStomach Neoplasms

Phase 2

Perioperative Therapies in Locally Advanced Unresectable Gastric Cancer

RecruitingNCT06630130

Jeeyun LeeStomach Neoplasms

Start: 2025-01-22End: 2029-06-30Target: 100Updated: 2026-07-01

A Study of Novel Agents or Combinations as Perioperative Treatment in Participants With Locally Advanced Resectable Gastroesophageal Adenocarcinoma

RecruitingNCT07069712

AstraZenecaGastroesophageal Adenocarcinoma

Start: 2025-07-17End: 2029-07-16Target: 100Updated: 2026-08-17

Phase 3

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

RecruitingNCT07431281

AstraZenecaGastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer

Start: 2026-02-03End: 2031-10-27Target: 2130Updated: 2026-09-09

Related Papers

GEMINI-Perioperative (PeriOp) Gastric: A phase 2 study of novel agent-based combinations as PeriOp therapy for previously untreated, locally advanced resectable gastric, gastroesophageal junction (GEJ), or esophageal adenocarcinoma.

Journal of Clinical Oncology2026-01-10